Publicaciones en colaboración con investigadores/as de Duke University (20)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2022

  1. Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity

    Developmental Cell, Vol. 57, Núm. 3, pp. 310-328.e9

2021

  1. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

    Nature Genetics, Vol. 53, Núm. 9, pp. 1311-1321

  2. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

    Blood, Vol. 137, Núm. 9, pp. 1154-1165

2020

  1. DNA methylation and body mass index from birth to adolescence: meta-analyses of epigenome-wide association studies

    Genome Medicine, Vol. 12, Núm. 1

  2. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2019

  1. Epigenome-wide meta-analysis of DNA methylation and childhood asthma

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 6, pp. 2062-2074

2017

  1. Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: Findings from the pregnancy and childhood epigenetics (PACE) consortium

    Human Molecular Genetics, Vol. 26, Núm. 20, pp. 4067-4085

2016

  1. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 31-39

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  3. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2013

  1. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration

    Nature Chemical Biology, Vol. 9, Núm. 9, pp. 586-594

  2. Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication

    Retrovirology, Vol. 10, Núm. 1

2011

  1. Identifying polyglutamine protein species in situ that best predict neurodegeneration

    Nature Chemical Biology, Vol. 7, Núm. 12, pp. 925-934

2010

  1. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis

    Journal of Neuroscience, Vol. 30, Núm. 31, pp. 10541-10550

2009

  1. A kernel for open source drug discovery in tropical diseases

    PLoS Neglected Tropical Diseases, Vol. 3, Núm. 4

  2. A kernel for the tropical disease initiative

    Nature Biotechnology

  3. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome

    Journal of Cell Biology, Vol. 187, Núm. 7, pp. 1083-1099